1.58
0.06 (3.95%)
| Penutupan Terdahulu | 1.52 |
| Buka | 1.52 |
| Jumlah Dagangan | 468,777 |
| Purata Dagangan (3B) | 963,688 |
| Modal Pasaran | 125,779,224 |
| Harga / Pendapatan (P/E TTM) | 31.60 |
| Harga / Pendapatan (P/E Ke hadapan) | 15.04 |
| Harga / Jualan (P/S) | 2.17 |
| Harga / Buku (P/B) | 2.78 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 12 Aug 2025 - 18 Aug 2025 |
| Margin Keuntungan | 6.54% |
| Margin Operasi (TTM) | -40.99% |
| EPS Cair (TTM) | 0.050 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 169.80% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 11.58% |
| Nisbah Semasa (MRQ) | 2.49 |
| Aliran Tunai Operasi (OCF TTM) | 8.67 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -3.29 M |
| Pulangan Atas Aset (ROA TTM) | 3.53% |
| Pulangan Atas Ekuiti (ROE TTM) | 10.42% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menurun | Menurun |
| Biotechnology (Global) | Menurun | Menurun | |
| Stok | Protalix BioTherapeutics, Inc. | - | - |
AISkor Stockmoo
| Konsensus Penganalisis | -2.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -2.0 |
| Purata Bergerak Teknikal | 2.5 |
| Osilator Teknikal | -0.5 |
| Purata | -0.50 |
|
Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company offers Elelyso for the treatment of Gaucher disease. It also develops PRX-102, a therapeutic protein candidate for the treatment of Fabry disease; PRX-115, a plant cell-expressed recombinant PEGylated Uricase for the treatment of gout; and PRX-119, a plant cell-expressed PEGylated recombinant human DNase I product candidate for the treatment of NETs-related diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz (Fiocruz); and Chiesi Farmaceutici S.p.A. The company was incorporated in 1993 and is based in Hackensack, New Jersey. Protalix BioTherapeutics, Inc. is a subsidiary of Protalix Ltd. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| % Dimiliki oleh Orang Dalam | 10.39% |
| % Dimiliki oleh Institusi | 10.78% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Stratos Wealth Partners, Ltd. | 31 Mar 2025 | 346,400 |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
| Tarikh | Jenis | Butiran |
|---|---|---|
| 14 May 2025 | Pengumuman | Protalix BioTherapeutics to Present at the 3rd Annual H.C. Wainwright BioConnect Investor Conference at Nasdaq NYC |
| 09 May 2025 | Pengumuman | Protalix BioTherapeutics Reports First Quarter 2025 Financial and Business Results |
| 05 May 2025 | Pengumuman | Protalix BioTherapeutics to Announce First Quarter 2025 Financial and Business Results on May 9, 2025 |
| 24 Mar 2025 | Pengumuman | Protalix BioTherapeutics to Present at the iAccess Alpha Virtual Best Ideas Spring Conference 2025 |
| 17 Mar 2025 | Pengumuman | Protalix BioTherapeutics Reports Fiscal Year 2024 Financial and Business Results |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |